The biotech start-up, which was based in 2019 and is predicated in Navarra within the north of Spain, is concentrated on creating and commercializing probiotics and postbiotics for weight problems and its related problems reminiscent of insulin resistance, prediabetes and kind 2 diabetes.
In simply six years, the corporate has used its validated improvement platform to substantiate the anti-diabetes potential of its Pediococcus acidilactici pressure by way of research in Caenorhabditis elegans and rodents to people. Its pA1c pressure has been studied in each its reside (probiotic) and warmth inactivated (postbiotic) types, with essentially the most just lately revealed papers specializing in the postbiotic, which the corporate calls pA1cHI.
“The postbiotic type is efficient and protected and affords larger stability,” Josune Ayo, CEO of Genbioma, instructed NutraIngredients. “It additionally affords value advantages since you don’t want the overages within the closing product to make sure you’re assembly label declare, such as you want with a probiotic.”
A paper revealed final week in Vitamin detailed knowledge from a randomized, double-blind, placebo-controlled pilot research that included 17 overweight topics with and with out prediabetes receiving both pA1cHI (10 billion complete cells) or placebo for 12 weeks.
The information confirmed that members within the postbiotic group not solely displayed important reductions in HbA1c (glycated hemoglobin, a marker of long-term presence of extra glucose within the blood) but in addition skilled important decreases in physique weight (-1.46 kg, or -3.2 lbs), BMI (-0.5 factors) and fats mass (-890 grams, or -2.0 lbs), whereas lean mass elevated by 210 grams (0.46 lbs)
Diastolic blood stress additionally improved after postbiotic supplementation, with a mean discount of 8.8 mmHg reported by the researchers.
“This pilot trial highlights pA1cHI as a possible postbiotic intervention for enhancing metabolic well being, significantly amongst people with PreD and weight problems,” wrote researchers from Genbioma, Hospital Universitario Vinalopó and Sandwalk Bioventures SL. “The statistically important and clinically related reductions in HbA1c counsel that pA1cHI may play a pivotal position in stopping the development from prediabetes to T2D.
“Moreover, contemplating the growing prevalence of metabolic issues globally, pA1cHI presents a novel and efficient method not just for managing current circumstances reminiscent of PreD and weight problems but in addition as a preventive technique in opposition to the onset of T2D.”
The ingredient is now being investigated in a bigger trial with folks with kind 2 diabetes, Ayo stated.
Understanding the mechanisms of motion
These human trials are the fruits of a number of pre-clinical research documented in nearly 10 papers published in peer-reviewed scientific journals since 2022.
These earlier papers detailed the mechanisms of motion, with knowledge revealed earlier this yr within the Worldwide Journal of Molecular Science (2025) displaying that the postbiotic could modulate gene expression linked to lipid oxidation, fatty acid synthesis, insulin signaling and oxidative stress in a C. elegans mannequin of prediabetes.
The identical paper reported that combining pA1cHI with chromium picolinate and zinc enhanced the metabolic advantages.
One other paper revealed this yr within the Worldwide Journal of Molecular Science introduced outcomes from experiments with mice consuming a high-fat food plan. The postbiotics was discovered to stimulate the secretion of GLP-1 together with modifications to the intestine microbiota and enhancements in intestinal barrier perform.
“Some of the related findings is the elevated colonic expression of GLP-1, an incretin hormone secreted by intestinal L-cells,” the researchers wrote. “This impact might be attributed to the direct motion of postbiotic metabolites (reminiscent of short-chain fatty acids or bacterial structural parts) on particular receptors of L-cells, selling their activation and hormone secretion.
“Given the well-known results of GLP-1 on satiety, insulin sensitivity and irritation discount, this mechanism may assist clarify a number of of the noticed results, together with the diminished meals consumption, [body weight] loss and enhancements in hepatic and adipose tissue metabolism.”
The corporate’s potential was acknowledged early on by NutraIngredients, which named Genbioma a Probiota Pioneer at Probiota 2022 in Copenhagen.
From lab bench to retail shelf
Having established a robust scientific basis, Genbioma is now bringing the elements to market, with industrial merchandise set to launch in seven or eight nations throughout the Balkans later this yr.
To finance growth initiatives, Ayo stated Genbioma is presently seeking to elevate €2 million, which shall be used for scientific analysis and enterprise improvement. The corporate can also be seeking to create an exterior scientific advisory board, she stated.
One other postbiotic can also be being explored for ldl cholesterol administration, she stated, with plans to scale that up subsequent yr.
Sources: Vitamin. doi: 10.1016/j.nut.2025.112948. “Preliminary impact of the postbiotic pA1cHI in glucose metabolism of overweight people. A pilot, randomized, double-blind, managed dietary intervention”. Authors: D. Yavorov-Dayliev, et al.
Worldwide Journal of Molecular Science, 2025. doi: 10.3390/ijms26136408. “Warmth-Inactivated Pediococcus acidilactici pA1cHI Maintains Glycemic Management and Prevents Physique Weight Achieve in Excessive-Fats-Weight loss program-Fed Mice”. Authors: M. Cabello-Olmo, et al.
Life Sciences, 2025. doi: 10.1016/j.lfs.2024.123359. “Pediococcus acidilactici CECT 9879 (pA1c) and warmth inactivated pA1c (pA1c HI) ameliorate gestational diabetes mellitus in mice”. Authors: D. Yavorov-Dayliev, et al.
Worldwide Journal of Molecular Science, 2025. doi: 10.3390/ijms26168094. “Postbiotic pA1cHI for Stopping Insulin Resistance and Weight problems in a Caenorhabditis elegans Mannequin of Prediabetes”. Authors: D. Yavorov-Dayliev, et al.
